Our clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make the difference in their everyday lives.
Shield Therapeutics is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru®
Find out moreAccrufer®/Feraccru® is a novel oral product that addresses the needs of patients who cannot tolerate existing oral iron products and offers a clear alternative to IV iron therapy.
Find out moreThe content of all investor relations materials contained on this website are deemed to be correct at the time of issue/publication.
RT @proactive_UK: $STX Shield Therapeutics completes the formalities on US$10mln loan https://t.co/1w7l1YbRBO @shieldTx $SHIEF $1JS #STX #…
RT @WalbrookPR: Shield Therapeutics plc (AIM: #STX, @ShieldTx) completion of loan agreement / partial conversion 💰US$10m loan agreed w/ AO…
RT @AimforProfit: #STX Shield Therapeutics partner makes new drug submission in Canada https://t.co/y7go8HG6Up @shieldTx $SHIEF $1JS #STX #…
